Supercharged immune cells take on tough melanoma
NCT ID NCT05628883
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infused back after a short course of chemotherapy. The goal was to see if this approach is safe and can shrink tumors in 17 participants with various types of melanoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TBio-4101 (a personalized immune cell therapy using the patient's own tumor-fighting T-cells)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced melanoma that has not responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 17 participants, so results may not apply to everyone. The treatment involves strong chemotherapy and can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States